Psoriasis is a common chronic, immune-mediated, skin disease with a significantly negative impact on patients' quality of life. It is one of papulosquamous diseases defined by erythematous plaques with silvery scales.
The interplay among cytokines released by dendritic, Th1, Th2, and Th17 cells leads to the clinical manifestations seen in psoriasis. Although discovering novel biomarkers for psoriasis is challenging step., it may play an essential role in diagnosis, severity assessment and prediction of treatment outcome and prognosis of the disease
Patients with moderate to severe plaque psoriasis.
No restriction of age, race nor occupation.
History of psoriasis treatment with systemic and biological agents prior to the study for at least 3 months.
Pregnancy and lactation.
Infections.
Patients with chronic diseases: hepatic disorders, hematologic diseases, chronic renal failure or cancer.